HC Wainwright Reiterates Buy Rating for Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $17.00 price target on the stock. HC Wainwright's price objective suggests a potential upside of 150.37% from the company's previous close.

Separately, Guggenheim dropped their target price on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, March 24th.

Valneva Stock Up 3.3 %

Shares of Valneva stock traded up $0.22 on Tuesday, hitting $6.79. The company had a trading volume of 12,728 shares, compared to its average volume of 37,059. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a 50-day moving average of $6.97 and a 200-day moving average of $5.66. The firm has a market capitalization of $551.76 million, a P/E ratio of -52.23 and a beta of 1.85.

Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Research analysts predict that Valneva will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently modified their holdings of the business. ABC Arbitrage SA bought a new stake in Valneva in the 4th quarter valued at about $84,000. GAMMA Investing LLC acquired a new position in Valneva in the 1st quarter valued at $94,000. Finally, Wells Fargo & Company MN lifted its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after acquiring an additional 30,859 shares during the period. Institutional investors own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.